Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CD19/CD20 or CD19/CD22 CAR-T in R/R B-cell Malignancies
NCT03398967Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells in B-cell leukemia (BCL), B cell lymphoma, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT03398967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398967.